Axitinib
Sign in to save this workspacePrimary targets: FLT1_VEGFR1, KDR_VEGFR2, FLT4_VEGFR3 · FDA status: FDA Approved
Selectivity scorecard
KISS
93.23
Gini
0.688
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Axitinib. Strongest target: AURORA_A at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | AURORA_A | 100.0% | 0.0% |
| 2 | ABL1 | 99.4% | 0.6% |
| 3 | TNIK | 99.0% | 1.0% |
| 4 | FLT4_VEGFR3 | 98.5% | 1.5% |
| 5 | ABL2_ARG | 98.3% | 1.7% |
| 6 | FLT1_VEGFR1 | 98.1% | 1.9% |
| 7 | KDR_VEGFR2 | 96.9% | 3.1% |
| 8 | FGFR2 | 96.1% | 3.9% |
| 9 | PDGFRA | 96.0% | 4.0% |
| 10 | FMS | 95.2% | 4.8% |
| 11 | AURORA_B | 95.1% | 4.9% |
| 12 | FGFR1 | 94.9% | 5.1% |
| 13 | ROS_ROS1 | 93.7% | 6.3% |
| 14 | AMPK(A1_B2_G2) | 93.7% | 6.3% |
| 15 | AMPK(A1_B2_G3) | 93.6% | 6.4% |
| 16 | MINK_MINK1 | 93.4% | 6.6% |
| 17 | AMPK(A1_B2_G1) | 93.3% | 6.7% |
| 18 | FGFR3 | 93.1% | 6.9% |
| 19 | AMPK(A2_B2_G2) | 93.0% | 7.0% |
| 20 | PDGFRB | 92.9% | 7.1% |
Selectivity landscape
Where Axitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Axitinib.
Atlas insights for Axitinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.829 |
| EPT0291 | EPN | 0.825 |
| SRR10899984 | — | 0.814 |
| aMVAC.P_005_TURBT_S223 | — | 0.810 |
| SRR12202498 | — | 0.802 |
Annotations
Sign in to read and post annotations.
Loading…